Search for compounds against Parkinson's Disease in High-throughput screening
Innovation Award for Münster-based Max Planck Researcher: New procedure for phenotypic screening on stem cells
Scientists of the Max Plank Institute for Molecular Biomedicine in Münster have advanced a method and in this way improved it for industrial use to identify potential pharmaceutical compounds against neurodegenerative diseases, such as Alzheimer's or Parkinson's Disease, in a fast and reliable manner. The patented procedure enables the cultivation of stem cells to be suitable for in-vivo high-throughput compound screening. The "Work group of BioRegions in Germany" honors the technology with the Innovation Award 2012 at the German Biotechnology Day in Frankfurt today.